Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 255.29
(-2.5%)
USD 255.29
(-2.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.58 Billion USD | 7.09% |
| 2022 | 1.74 Billion USD | 28.06% |
| 2021 | 1.36 Billion USD | 24.67% |
| 2020 | 1.09 Billion USD | 549.41% |
| 2019 | -243.35 Million USD | 37.66% |
| 2018 | -390.37 Million USD | 36.56% |
| 2017 | -615.36 Million USD | -1310.83% |
| 2016 | -43.61 Million USD | 75.89% |
| 2015 | -180.89 Million USD | -140.62% |
| 2014 | -75.17 Million USD | -41.4% |
| 2013 | -53.16 Million USD | -3.43% |
| 2012 | -51.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2 Billion USD | 7.08% |
| 2024 Q3 | 1.39 Billion USD | -4.7% |
| 2024 Q2 | 1.45 Billion USD | -27.15% |
| 2023 Q4 | 1.86 Billion USD | 14.65% |
| 2023 Q3 | 1.63 Billion USD | -17.98% |
| 2023 Q2 | 1.98 Billion USD | 1.62% |
| 2023 Q1 | 1.95 Billion USD | 12.07% |
| 2023 FY | 1.86 Billion USD | 7.09% |
| 2022 Q3 | 1.51 Billion USD | -8.43% |
| 2022 Q2 | 1.65 Billion USD | -1.13% |
| 2022 Q1 | 1.67 Billion USD | 23.0% |
| 2022 FY | 1.74 Billion USD | 28.06% |
| 2022 Q4 | 1.74 Billion USD | 15.0% |
| 2021 Q3 | 825.18 Million USD | -27.86% |
| 2021 FY | 1.36 Billion USD | 24.67% |
| 2021 Q4 | 1.36 Billion USD | 65.24% |
| 2021 Q2 | 1.14 Billion USD | -7.66% |
| 2021 Q1 | 1.23 Billion USD | 16.94% |
| 2020 Q2 | 715.08 Million USD | 472.44% |
| 2020 Q4 | 1.05 Billion USD | 25.57% |
| 2020 FY | 1.09 Billion USD | 549.41% |
| 2020 Q1 | -191.99 Million USD | 29.16% |
| 2020 Q3 | 843.58 Million USD | 17.97% |
| 2019 Q3 | -646.84 Million USD | 21.98% |
| 2019 Q1 | -412.65 Million USD | -5.77% |
| 2019 FY | -243.35 Million USD | 37.66% |
| 2019 Q4 | -271.04 Million USD | 58.1% |
| 2019 Q2 | -829.07 Million USD | -100.91% |
| 2018 Q2 | -331.45 Million USD | 9.47% |
| 2018 Q1 | -366.14 Million USD | 40.5% |
| 2018 FY | -390.37 Million USD | 36.56% |
| 2018 Q4 | -390.14 Million USD | -36.13% |
| 2018 Q3 | -286.6 Million USD | 13.53% |
| 2017 FY | -615.36 Million USD | -1310.83% |
| 2017 Q4 | -615.36 Million USD | -1082.36% |
| 2017 Q3 | -52.04 Million USD | 79.88% |
| 2017 Q2 | -258.67 Million USD | -1127.15% |
| 2017 Q1 | -21.07 Million USD | 51.67% |
| 2016 Q4 | -43.61 Million USD | -136.01% |
| 2016 FY | -43.61 Million USD | 75.89% |
| 2016 Q1 | -231.27 Million USD | -27.85% |
| 2016 Q2 | -121.07 Million USD | 47.65% |
| 2016 Q3 | -18.48 Million USD | 84.74% |
| 2015 Q4 | -180.89 Million USD | -21.23% |
| 2015 Q3 | -149.21 Million USD | 1.35% |
| 2015 Q2 | -151.26 Million USD | 50.66% |
| 2015 Q1 | -306.58 Million USD | -307.8% |
| 2015 FY | -180.89 Million USD | -140.62% |
| 2014 Q2 | -80.72 Million USD | 76.97% |
| 2014 Q3 | -82.72 Million USD | -2.47% |
| 2014 Q4 | -75.17 Million USD | 9.12% |
| 2014 Q1 | -350.58 Million USD | -559.39% |
| 2014 FY | -75.17 Million USD | -41.4% |
| 2013 FY | -53.16 Million USD | -3.43% |
| 2013 Q2 | -24.97 Million USD | 74.46% |
| 2013 Q3 | -11.84 Million USD | 52.59% |
| 2013 Q4 | -53.16 Million USD | -349.06% |
| 2013 Q1 | -97.8 Million USD | -90.26% |
| 2012 Q4 | -51.4 Million USD | 0.0% |
| 2012 FY | -51.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 1639.885% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 5178.409% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -700.407% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -4872.015% |
| bluebird bio, Inc. | 108.57 Million USD | -1360.175% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 17683.485% |
| Imunon, Inc. | -4.69 Million USD | 33835.58% |
| Editas Medicine, Inc. | -87.11 Million USD | 1919.789% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 87.668% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 24.435% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1699.463% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -794.149% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 4828.508% |
| Verastem, Inc. | -37.27 Million USD | 4352.715% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 80.749% |
| Waters Corporation | 1.96 Billion USD | 19.134% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 94.093% |
| Biogen Inc. | 6.28 Billion USD | 74.789% |
| Nektar Therapeutics | 210.24 Million USD | -654.056% |
| Perrigo Company plc | 3.32 Billion USD | 52.279% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1386.685% |
| Illumina, Inc. | 1.21 Billion USD | -30.587% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -22651.287% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1492.005% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -992.756% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -21958.258% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -318.57% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 22428.549% |
| Evolus, Inc. | 63.7 Million USD | -2388.427% |
| Adicet Bio, Inc. | -142 Million USD | 1216.365% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 4407.486% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 5949.915% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -245.614% |
| FibroGen, Inc. | 56.76 Million USD | -2692.691% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -38.457% |
| OPKO Health, Inc. | 230.68 Million USD | -587.232% |
| Homology Medicines, Inc. | 18.43 Million USD | -8498.617% |
| Geron Corporation | 14.76 Million USD | -10639.97% |
| Exelixis, Inc. | -73.05 Million USD | 2270.194% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 3021.939% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 1149.719% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1523.069% |
| Zoetis Inc. | 4.76 Billion USD | 66.709% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 893.374% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 15841.505% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 116.576% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 10979.268% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -50.372% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -63.71% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 1270.847% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -14.806% |
| Blueprint Medicines Corporation | 702.83 Million USD | -125.561% |
| Insmed Incorporated | 721.62 Million USD | -119.69% |
| TG Therapeutics, Inc. | 17.86 Million USD | -8775.417% |
| Incyte Corporation | -3.17 Billion USD | 149.93% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -107.016% |